A Partial Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Anastrozole [MPI 674; Meditrina], an Aromatase Inhibitor, on Endometrial Thickness in Healthy Premenopausal Women When Dosed at Various Times During the Menstrual Cycle (Protocol M-001)

Trial Profile

A Partial Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Anastrozole [MPI 674; Meditrina], an Aromatase Inhibitor, on Endometrial Thickness in Healthy Premenopausal Women When Dosed at Various Times During the Menstrual Cycle (Protocol M-001)

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2009

At a glance

  • Drugs Anastrozole (Primary)
  • Indications Breast cancer
  • Focus Pharmacodynamics
  • Sponsors Meditrina Pharmaceuticals
  • Most Recent Events

    • 06 Feb 2008 Status changed from recruiting to completed according to a Meditrina Pharmaceuticals media release.
    • 12 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top